Patents by Inventor Soren Østergaard
Soren Østergaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230220021Abstract: The present invention relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, as well as their use in treatment of excitotoxic-related diseases and neuropathic pain.Type: ApplicationFiled: June 11, 2021Publication date: July 13, 2023Inventors: Javier Rodriguez Balboa, Kristian Strømgaard, Søren Østergaard
-
Publication number: 20220189270Abstract: An electronic theft-preventing system, including a first and a second multi-axis magnetometer and configured to output first and second vector signals representing movement of first and second magnetic field vectors; and a signal processor receiving the first and second vector signals, and configured to determine a multi-dimensional transformation, in accordance with optimization of a difference between the second vector signal and a compensation signal; wherein the compensation signal is generated from a transformation of the first vector signal in accordance with the multi-dimensional transformation; and generate a compensated second vector signal from the second vector signal and the first compensation signal. Determining that a detector signal meets a predefined criterion; and in response to at least the determining that the detector signal meets the predefined criterion, raising or forgo raising an alarm that warns about a possible theft-related event.Type: ApplicationFiled: April 8, 2020Publication date: June 16, 2022Applicant: ALERT SYSTEMS APSInventors: Verner FALKENBERG, Søren Østergaard SANDAL
-
Patent number: 8865868Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.Type: GrantFiled: August 6, 2009Date of Patent: October 21, 2014Assignee: Novo Nordisk Healthcare AGInventors: Carsten Behrens, Patrick William Garibay, Søren Østergaard, Henrik Sune Andersen, Nils Langeland Johansen, Bernd Peschke, Sonja Bak
-
Publication number: 20130039923Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.Type: ApplicationFiled: September 7, 2012Publication date: February 14, 2013Applicant: Novo Nordisk A/SInventors: Jesper Pass, Søren Østergaard, Jes Thorn Clausen
-
Patent number: 8287861Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.Type: GrantFiled: June 30, 2009Date of Patent: October 16, 2012Assignee: Novo Nordisk A/SInventors: Jesper Pass, Søren Østergaard, Jes Thorn Clausen
-
Publication number: 20110275559Abstract: The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation.Type: ApplicationFiled: May 18, 2009Publication date: November 10, 2011Applicant: Novo Nordisk A/SInventors: Søren Østergaard, Sanne Møller Knudsen, Jane Spetzler, Rasmus Jørgensen, Jacob Kofoed
-
Publication number: 20110223151Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.Type: ApplicationFiled: August 6, 2009Publication date: September 15, 2011Applicant: Novo Nordisk Health Care AGInventors: Carsten Behrens, Patrick William Garibay, Soren Østergaard, Henrik Sune Andersen, Johansen Nils Langeland, Peschke Bernd, Bak Sonja
-
Publication number: 20110091475Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/AL20R2 and IL22R1/AL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treat-ing various diseases and disorders, including autoimmune or inflammatory diseases or disorders.Type: ApplicationFiled: June 30, 2009Publication date: April 21, 2011Applicant: Novo Nordisk A/SInventors: Jesper Pass, Soren Østergaard, Jes Thorn Clausen
-
Publication number: 20100261637Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: ApplicationFiled: September 5, 2008Publication date: October 14, 2010Applicant: Novo nordisk A/SInventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Søren Østergaard, Steffen Reedtz-Runge, Henning Thøgersen
-
Patent number: 7026282Abstract: A novel set of inhibitors of the binding interaction between human urokinase plasminogen activator (uPA) and its cell surface receptor (uPAR) has been developed. The inhibitors comprise of peptide fragments, monomeric or in multiple copies attached to a common scaffold, in which the amino acid sequence may include uncommon substituted amino acids to partially comprise of peptoid sequences. The present invention also relates to the use of such peptides in therapy, in particular for the treatment of cancer, having developed a modified non-human mammalian receptor to which the novel inhibitors are antagonistic.Type: GrantFiled: July 1, 1999Date of Patent: April 11, 2006Assignee: Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning)Inventors: Michael Ploug, Søren Østergaard, Claus Holst-Hansen, Ross Stephens, Keld Danø, Arne Holm
-
Patent number: 6875741Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.Type: GrantFiled: September 24, 2001Date of Patent: April 5, 2005Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schäffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Søren Østergaard, Per Hertz Hansen
-
Patent number: 6716574Abstract: A diagnostic method is disclosed which utilizes short C-terminal fragments of Borrelia burgdorferi sensu lato derived protein OspC. The 4 amino-terminal acids Pro-Lys-Pro (SEQ ID NO: 22) are shown to be essential in immune reactivity between sera from patients suffering from early borreliosis and various OspC derivatives and it is shown that in order to be effective as a diagnostic agent, 5 consecutive amino acid residues long homologue of a fragment identical to the 10 C-terminal amino acids of OspC (SEQ DI NO: 1). Also disclosed are vaccines utilizing the short peptides as well as methods for their preparation.Type: GrantFiled: October 10, 2001Date of Patent: April 6, 2004Assignee: Dako A/SInventors: Marianne Jartved Mathiesen, Michael Theisen, Arne Holm, Søren Østergaard